华润双鹤：全资子公司平衡盐冲洗液获药品注册证书

Core Viewpoint - China Resources Double Crane announced that its wholly-owned subsidiary, Jingxi Double Crane, received the Drug Registration Certificate for the balanced salt irrigation solution from the National Medical Products Administration, allowing it to be marketed [1] Group 1: Product Development - The drug is a sterile electrolyte solution suitable for surgical irrigation and is considered to have passed the consistency evaluation [1] - Research and development for this product began in January 2022 and received approval in February 2026 [1] - Cumulative R&D investment reached 3.6531 million yuan as of the announcement date [1] Group 2: Market Potential - The global sales forecast for the drug in 2024 is approximately 3.3442 million USD, while the total domestic market sales are projected to be 55.85 million yuan [1] - The approval of this drug will enrich the company's product line and enhance its competitiveness [1] - However, there is uncertainty regarding the sales performance of the product [1]